StackTerminal.Health

BETA
Research compound

This compound is primarily studied in research/clinical settings & may not be widely available as a regulated over-the-counter supplement. Information is provided for educational purposes only — not as a recommendation to use. See our Safety page.

LL-37 (Cathelicidin)

LL-37 is an antimicrobial peptide involved in wound healing and immune modulation, with potential benefits for chronic wounds and infections.

immuneantimicrobialwound-healinganti-inflammatory
Evidence last reviewed: 19 Apr 2026
Supplement note
Private note on this supplement

Save how you reacted, what dose worked, what to watch for, or anything you want to remember later in your Notes tab.

Sign in to keep a private note on LL-37 (Cathelicidin).
Biomarkers studied
Outcomes directly measured across the evidence records below
Immune
Immune Function
Evidence
3 records
Antimicrobial activity
Patients with drug-resistant infectionsSystematic review
PUBMEDLow

Antimicrobial peptides, including LL-37, are implicated in managing periodontal and oral tissue conditions.

Dose: 0 mg
Focus on periodontal diseases and antimicrobial peptide expression.
Immune modulation
Critically ill patients with sepsisRCT
PUBMEDLow

Vitamin D promotes LL-37 synthesis, potentially aiding immune response in sepsis.

Dose: 0 mgDuration: 7 days
Study highlights the role of LL-37 in immune response modulation.
Wound healing
Patients with chronic woundsRCT
PUBMEDLow

LL-37 showed potential in enhancing wound healing in chronic wound patients.

Dose: 0 mgDuration: 4 weeksForm: Peptide
Study conducted in a murine model, extrapolated to human potential.
Forms
Peptide
Administered as an injection or topical application for localized effects.

Stacks containing LL-37 (Cathelicidin)

Public community stacks that include this ingredient.

Explore all stacks →
No public stacks include this ingredient yet.